ArticleResearch and practice in thrombosis and haemostasis2025
von Willebrand disease combined with other hemostasis disorders: an overlooked clinical entity.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
von Willebrand disease (VWD) is common, affecting ∼1% of the general population. Due to this relatively high prevalence, it can co-occur with other coagulation disorders. However, combined defects are often underrecognized in clinical practice. Diagnostic anchoring, overlapping symptoms, and limited access to comprehensive hemostatic and genetic testing contribute to these missed diagnoses. A growing number of case reports, case series, and cohort studies have documented the coinheritance of VWD with hemophilia A or B, rare coagulation factor deficiencies, and platelet function disorders. In some cohorts, up to one-third of cases with mild VWD had an additional hemostatic defect. Emerging genomic data also suggest that multiple low-frequency variants affecting hemostasis can co-occur in the same individual, particularly in populations with founder effects or high rates of consanguinity. Combined defects can alter bleeding severity, complicate diagnosis, and affect treatment decisions. Broader awareness and multidisciplinary evaluation are critical for addressing this underappreciated aspect of inherited bleeding disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.